3-(1H-indazol-5-yl)-2,2-dimethyl-3-phenylpropanoic acid | 1025762-66-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(1H-indazol-5-yl)-2,2-dimethyl-3-phenylpropanoic acid
• CAS: 1025762-66-6
• 化学式: C₁₈H₁₈N₂O₂
• 分子量: 294.353
• InChiKey: DBAPREUKIWGFEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(1H-indazol-5-yl)-2,2-dimethyl-3-phenylpropanoic acid 在 potassium phosphate 、 copper(l) iodide 、 二氧化碳 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 反应 24.0h， 生成 C₂₃H₂₁N₃O₂
  参考文献：
  名称：

  Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists

  摘要：

  Modification of a phenolic lead structure based on lessons learned from increasing the potency of steroidal glucocorticoid agonists lead to the discovery of exceptionally potent, nonsteroidal, indazole GR agonists. SAR was developed to achieve good selectivity against other nuclear hormone receptors with the ultimate goal of achieving a dissociated GR agonist as measured by human in vitro assays. The specific interactions by which this class of compounds inhibits GR was elucidated by solving an X-ray co-crystal structure. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.06.089
• 作为产物：
  描述：

  (1H-indazol-5-yl)(phenyl)methanol 在 四氯化钛 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 24.0h， 生成 3-(1H-indazol-5-yl)-2,2-dimethyl-3-phenylpropanoic acid
  参考文献：
  名称：

  Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists

  摘要：

  Modification of a phenolic lead structure based on lessons learned from increasing the potency of steroidal glucocorticoid agonists lead to the discovery of exceptionally potent, nonsteroidal, indazole GR agonists. SAR was developed to achieve good selectivity against other nuclear hormone receptors with the ultimate goal of achieving a dissociated GR agonist as measured by human in vitro assays. The specific interactions by which this class of compounds inhibits GR was elucidated by solving an X-ray co-crystal structure. (C) 2013 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.06.089

文献信息

• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Sheppeck James E.

  公开号：US20100076014A1

  公开（公告）日：2010-03-25

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一些新型非类固醇化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节有关的疾病方面具有用途，包括炎症和免疫性疾病、肥胖和糖尿病，其结构为公式（I），其对映体、顺反异构体或其药学上可接受的盐或水合物，其中（Ia）为杂环或杂芳烃；J，Ja，E，F，G，Ma，M，Q，Za和Z的定义如本文所述。还提供了使用所述化合物治疗炎症或免疫相关疾病、肥胖和糖尿病的药物组合物和方法。
• Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US08067447B2

  公开（公告）日：2011-11-29

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了新型非甾体化合物，其有助于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括炎症和免疫性疾病、肥胖和糖尿病，其结构式（I），其对映体，二对映异构体或其药学上可接受的盐或水合物，其中（Ia）是杂环或杂环芳基；J，Ja，E，F，G，Ma，M，Q，Za和Z如本文所定义。还提供了制药组合物和使用该化合物治疗炎症或免疫相关疾病以及肥胖和糖尿病的方法。
• WO2008/57856
  申请人：——

  公开号：——

  公开（公告）日：——
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF
  申请人：Bristol-Myers Squibb Company

  公开号：EP2094692B1

  公开（公告）日：2012-11-28
• US8067447B2
  申请人：——

  公开号：US8067447B2

  公开（公告）日：2011-11-29